IBEX 35
11.154,60 +170,90 (+1,56%) Euro Stoxx 50
5.006,85 +67,84 (+1,37%) Dólar/Euro
1,0699 -0,0034 (-0,32%) Petróleo Brent
89,36 +0,35 (+0,39%) Oro
2.349,60 +7,10 (+0,30%) Bitcoin EUR
58.846,44 -1.371,08 (-2,28%)
TG Therapeutics, Inc. (TGTX)
Después del cierre:
TG Therapeutics, Inc.
3020 Carrington Mill Blvd.
Suite 475
Morrisville, NC 27560
United States
212 554 4484
https://www.tgtherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 264
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael S. Weiss Esq. | Chairman, CEO & President | 1,97M | N/A | 1966 |
| Mr. Sean A. Power CPA | CFO, Corporate Secretary & Treasurer | 652,6k | N/A | 1982 |
| Jenna Bosco | Senior Vice President of Corporate Communications | N/A | N/A | N/A |
| Mr. Adam Waldman | Chief Commercialization Officer | N/A | N/A | N/A |
Descripción
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Gobierno corporativo
El ISS Governance QualityScore de TG Therapeutics, Inc., a día 1 de abril de 2024, es 10. Las puntuaciones base son Auditoría: 5; Tablero: 10; Derechos de los accionistas: 5; Compensación: 10.
